联合检测大肠癌患者外周血CK20和CEA的临床意义

Clinical value of combined detection of CK20 and CEA in peripheral blood of patients with colorectal cancer

目的探讨同时检测2种肿瘤标志物与大肠癌的临床意义。方法应用逆转录-聚合酶链反应(RT-PCR)方法和酶联免疫法联合检测157例患者外周血中细胞角蛋白(CK20)和癌胚抗原(CEA)。结果CK20、CEA联合检测总阳性率90.79%,明显高于单项检测的阳性率77.63%和67.11%;其阳性结果与病理分期有关。结论CK20和CEA阳性表达是大肠癌患者外周血存在癌细胞的重要证据,提示预后不良,联合检测CK20、CEA可提高大肠癌的检出率。

Objective To evaluate the clinical value of the combined detection of CK20 and CEA in peripheral blood of patients with colorectal cancer. Methods The expression of CK20 and CEA was detected by RT-PCR and ELISA in 157 patients with colorectal cancer. Results The positive rate of CK20 and CEA in peripheral blood was 90.79% . The positive rate was significantly higher than other groups. The overall positive rate of CK20 and CEA was significantly correlated with Dukes stage. Conclusion The combined positive expression of CK20 and CEA is an important evidence revealing the existence of tumor cells in peripheral blood of patients with colorectal cancer, demonstrating a poor prognosis.